Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
Table 4
Pharmacokinetics of darunavir, ritonavir, and etravirine (intense pharmacokinetic sampling).
Week 4
Week 24
Week 48
Mean ± SD
, ng·h/mL
, ng/mL
, ng·h/mL
, ng/mL
, ng·h/mL
, ng/mL
Darunavir
Overall
32
26
22
20
21
21
Men
Overall
10
8
8
6
9
9
Black
6
4
5
4
4
5
Hispanic
3
4
3
2
4
3
White
1
—
—
—
—
—
—
1
5550
1
Women
Overall
22
18
14
14
12
12
Black
16
14
11
10
9
8
Hispanic
5
3
3
4
3
4
White
1
4310
1
—
—
—
—
—
—
—
—
Ritonavir
Overall
32
26
22
402 ± 326
20
21
21
Men
Overall
10
8
8
6
9
9
Black
6
4
5
4
7633 ± 3297
4
5
Hispanic
3
4
3
2
4
3
White
2755
1
—
—
—
—
—
—
8639
1
537
1
Women
Overall
22
18
14
14
12
12
Black
16
14
11
10
9
8
Hispanic
5
3
3
4
3
4
White
9782
1
491
1
—
—
—
—
—
—
—
—
Etravirine
Overall
16
14
10
13
9
12
Men
Overall
8
6
4
6
5
6
Black
4
3
2
2
2027
1
2
Hispanic
3
3
2
3
3
3
White
1
—
—
—
—
1100
1
1
846
1
Women
Overall
8
8
6
7
4
6
Black
7
7
5
6
4
5
Hispanic
6918
1
670
1
9362
1
783
1
—
—
253
1
SD: standard deviation;: area under the plasma concentration–time curve over 12 hours; : trough concentration.
